Clinical Trials Browser

Active not recruiting × Has results × durvalumab × Clear all

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03660826 2026-04-13

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 2 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase 2 Active not recruiting

301 enrolled 15 charts

Lung Cancer Metastatic

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04068610 2026-03-02

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1/2 Active not recruiting

61 enrolled 35 charts

Gastrointestinal

Colonic Neoplasms

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04176848 2026-02-18

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase 2 Active not recruiting

15 enrolled 7 charts

Breast Neoplasms

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03775486 2026-02-10

ORION

Phase 2 Active not recruiting

401 enrolled 26 charts

Non-small Cell Lung Cancer NSCLC

NCT03141359 2026-02-05

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Phase 2 Active not recruiting

61 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04999969 2026-02-03

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Phase 2 Active not recruiting

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03459846 2026-01-30

BAYOU

Phase 2 Active not recruiting

154 enrolled 13 charts

Urinary Bladder Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Endometrial Neoplasms

NCT04745689 2025-12-10

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Neoplasm Metastasis

NCT05061134 2025-07-31

MONETTE

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1/2 Active not recruiting

383 enrolled 48 charts

Neoplasm Metastasis

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Phase 2 Active not recruiting

18 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Phase EARLY_PHASE1 Active not recruiting

11 enrolled 6 charts

Thyroid Neoplasms

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

Phase 1/2 Active not recruiting

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms